MGC Pharma funded to drive projects proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Strong sales development driven by ArtemiC Strong sales development MGC Pharma develops and markets medicines using compounds derived from cannabis and.
MGC Pharmaceuticals progresses clinical trial planning for CimetrA, CannEpil and CogniCann
All three trials are well funded, following the successful £6.5 million IPO fundraising and listing on the London Stock Exchange in February 2021. Interim trial results are expected in Q3 2021 for CimetrA and Q4 2021 for CannEpil.
MGC Pharmaceuticals Ltd’s (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) major clinical trial programs planned for CimetrA™, CannEpil® and CogniCann® in 2021 are actively progressing across Australia, Israel and Brazil.
Commencement of the CimetrA Phase III to treat COVID-19 and CannEpil Phase IIb trials for treatment-resistant epilepsy are imminent and all the required regulatory approvals have been received for both.
MGC Pharmaceuticals Ltd progresses clinical trial planning for CimetrA, CannEpil and CogniCann proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.